Comprehensive Drug Discovery & Diagnostic Service for Sheeppox Virus

Overview

The Sheeppox virus (SPPV) belongs to the Capripoxvirus genus within the Poxviridae family, and it mainly targets sheep. This viral disease spreads easily between hosts and presents with clinical signs of fever and skin lesions, along with difficulty in breathing. The virus transmits through direct contact with infected animals, along with contact with contaminated equipment and bedding materials. Sheeppox results in considerable death rates among young or immunocompromised animals during severe cases of infection. Sheeppox manifests in both acute and chronic forms, while its clinical signs change based on the viral strain and how the host's immune system responds. The primary prevention strategies for sheeppox consist of vaccination and quarantine measures. Endemic outbreaks of the disease lead to significant economic damage within the sheep farming sector. Creative Biolabs provides complete preclinical research services for viral studies, which cover SPPV. Our team specializes in viral characterization and pathogenesis as well as vaccine development and antiviral drug screening. Our advanced technology delivers precise and consistent outcomes specifically designed for your research requirements.

Accelerated SPPV Preclinical Research Services

• For Therapeutics Development

In Vitro Antiviral Efficacy Assays

• Cytotoxicity Assays: To evaluate the toxicity of the drug in cultured cells (e.g., MTT, MTS, or LDH assays).
• Viral Inhibition Assays: These assays determine the drug's ability to inhibit Sheeppox virus replication, often by measuring viral load reduction in infected cells.
• Plaque Reduction Assays: Used to quantify the virus's ability to form plaques on a monolayer of cells, with reduced plaque formation indicating antiviral activity.
• Viral Binding and Entry Assays: To evaluate if the drug interferes with the virus's ability to bind to and enter host cells.
• Viral RNA Quantification (RT-qPCR or RT-PCR): Measures the levels of viral RNA post-treatment to assess inhibition of viral replication.

In Vivo Efficacy Studies (Animal Models)

• Acute Infection Models: These involve infecting animals with the Sheeppox virus to test the drug's therapeutic efficacy during the acute phase of infection.
• Pharmacokinetics Studies: To determine the absorption, distribution, metabolism, and excretion (ADME) profile of the drug in animals, as well as the optimal dosing regimen.
• Toxicology and Safety Studies: Evaluation of the drug's safety profile in animal models, including any potential organ toxicity, adverse effects, and overall clinical condition of the animals.
• Histopathological Examination: Tissue samples from infected animals are examined post-treatment to assess any pathological changes (e.g., organ damage, inflammatory response).
• Immune Response Profiling: Assessing the effect of the drug on the host's immune system, including antibody responses and T-cell activation.

• For Diagnostics Development

Antigen Detection Assays

• Enzyme-Linked Immunosorbent Assay (ELISA): Used to detect specific antigens produced by the Sheeppox virus.
• Lateral Flow Immunoassay (LFI): A rapid, point-of-care test that detects viral antigens in samples like blood, serum, or tissue swabs.
• Immunohistochemistry (IHC): This technique is used to detect viral antigens in tissue samples by using specific antibodies that bind to the antigen.
• Western Blotting: To identify specific proteins of the Sheeppox virus by separating them based on molecular weight and detecting them with specific antibodies.

Nucleic Acid Detection Assays

• Reverse Transcription Polymerase Chain Reaction (RT-PCR): One of the most sensitive and specific assays for detecting Sheeppox virus RNA.
• Real-Time PCR (qPCR): A quantitative version of RT-PCR, used to measure the amount of viral RNA in a sample.
• Loop-Mediated Isothermal Amplification (LAMP): A rapid, cost-effective alternative to PCR, which amplifies viral nucleic acids at a constant temperature, allowing for field testing.
• Next-Generation Sequencing (NGS): A more advanced method to sequence the virus's entire genome, used for detecting variants and mutations.
• In Situ Hybridization (ISH): A method for detecting viral RNA in tissue samples, useful for pinpointing infection sites in animals.

Antibody Detection Assays (Serology)

• Indirect ELISA: Used to detect specific antibodies (IgM or IgG) against Sheeppox virus in serum or plasma samples.
• Western Blotting for Antibodies: Identifies the specific antibodies produced against the virus's structural proteins, providing a detailed immune profile.
• Neutralization Assay: Measures the ability of antibodies to neutralize the virus, which is an indicator of protective immunity.
• Lateral Flow Immunoassay (LFI) for Antibodies: A point-of-care assay that detects the presence of IgM or IgG antibodies, offering a rapid test for previous or recent exposure to the virus.
• Immunofluorescence Assay (IFA): Uses fluorescently labeled antibodies to detect the presence of antibodies in serum.

Request a Quote

Products for SPPV Research

The monoclonal antibody of SPPV is highly specific and used for the accurate detection and research of viral antigens. It supports diagnostic assay development and immune response studies. The recombinant protein of SPPV provides a consistent source of viral antigen. It is valuable for serological testing, vaccine development, and functional analysis.

• Recombinant SPPV proteins or antigens

• Antibodies against SPPV proteins

Get a Quote Today

Applications

• The SPPV serves multiple essential purposes within veterinary science and biological research domains.
• The focus of research on SPPV involves creating vaccines and antiviral medications to manage outbreaks in sheep herds while protecting livestock industries from financial harm.
• Researchers use SPPV as a representative model to study other similar zoonotic poxviruses because of its shared characteristics.
• SPPV research on viral pathogenesis and immune responses helps scientists understand virus-host interactions and study viral genetics more effectively.
• Researchers are investigating SPPV-based vaccine platforms as potential solutions for vaccinating other livestock as well as humans because of the virus's established safety profile.

Advantages

• We deliver advanced technology combined with professional expertise to achieve precise and dependable outcomes in viral characterization, diagnostics, and therapeutic development.
• Our team possesses deep expertise in handling various viruses, which includes both emerging and zoonotic forms, to deliver project-specific solutions.
• Our research support extends through every phase, including preclinical studies, while also covering vaccine development and antiviral screenings.
• Our flexible service provisions address client-specific needs in academic research and pharmaceutical development, as well as outbreak investigation, to deliver virus-related solutions that are both cost-efficient and effective.

FAQs